ReviewAnnals of medicine and surgery (2012)2025
IgG4 unveiled: navigating the interplay with Crohn's disease - from immunology insights to machine learning.
Review in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease (CD) is a chronic inflammatory bowel disease characterized by relapsing-remitting episodes and a progressive course that often leads to bowel damage and disability. While the etiology of CD is multifactorial, involving genetic, environmental, and immunological factors, recent studies have highlighted the role of food antigens and the gut microbiome in its pathogenesis. This paper explores the immunological underpinnings of CD, with a focus on the elevated levels of serum immunoglobulin G4 (IgG4) and their correlation with disease severity and therapeutic response. We review clinical trials and case studies that demonstrate the potential of IgG4-guided exclusion diets and intravenous immunoglobulin (IVIG) therapy in ameliorating CD symptoms and inflammation. Additionally, we delve into advancements in machine learning (ML) models that utilize fecal microbiome data, offering promising diagnostic tools for distinguishing CD from ulcerative colitis and non-IBD conditions. The integration of ML in endoscopy and predictive models for therapy complications signifies a leap toward precision medicine in IBD management. This paper underscores the necessity for a nuanced understanding of CD's immunological aspects and the innovative application of ML in its diagnosis and treatment, paving the way for personalized therapeutic strategies and improved patient outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.